1 Min Read
NEW YORK, Nov 21 (Reuters) - Oncolytics Biotech Inc : * U.S.-listed shares up 15.5 percent to $2.91 in premarket after data from head and neck cancer drug trial
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.